Mezagitamab ( DrugBank: Mezagitamab )

2 diseases

ID	Disease name (Link within this page)	Number of trials
63	Idiopathic thrombocytopenic purpura	1
66	IgA nephropathy	2

63. Idiopathic thrombocytopenic purpura

Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004103-12-BG (EUCTR)	15/12/2020	22/06/2020	A Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Immune Thrombocyto ...	A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and ...	Primary immune thrombocytopenia MedDRA version: 23.0;Level: LLT;Classification code 10050245;Term: A ...	Product Name: TAK-079 Product Code: TAK-079 INN or Proposed INN: Mezagitamab Other descriptive name: TA ...	Takeda Development Center Americas, Inc. (Takeda)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	54	Phase 2	United States;Slovenia;Greece;Spain;Ukraine;Croatia;Bulgaria;Germany;Italy;Japan;China

Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05174221 (ClinicalTrials.gov)	November 9, 2022	14/12/2021	A Study of Mezagitamabin Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgroun ...	A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ...	Kidney Disease	Drug: Mezagitamab	Takeda	NULL	Recruiting	18 Years	N/A	All	16	Phase 1	United States;Australia;Belgium;China;Hungary;Italy;Japan;Korea, Republic of;Serbia;Singapore;Spain; ...
2	JPRN-jRCT2011220009	17/07/2022	15/06/2022	A Study of Mezagitamabin Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgroun ...	A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ...	Kidney Disease	TAK-079 (Mezagitamab) Mezagitamab, subcutaneous injection, once weekly for 8 weeks then once every 2 ...	Nishizawa Atsushi	NULL	Recruiting	>= 18age old	Not applicable	Both	16	Phase 1	Australia;China;Spain;Italy;South Korea;Serbia;Singapore;Taiwan;USA;Belgium;Hungary;UK;Japan